Quantum BioPharma Ltd.
QNTM
$30.18
$4.4517.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.17% | -25.69% | -35.32% | -40.51% | -50.69% |
| Depreciation & Amortization | -66.58% | -80.43% | -85.89% | -88.42% | -67.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.47% | -16.10% | -52.89% | -62.54% | -60.81% |
| Operating Income | -42.47% | 16.10% | 52.89% | 62.54% | 60.81% |
| Income Before Tax | -108.06% | 18.18% | 51.11% | 71.36% | 66.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -108.06% | 18.18% | 51.11% | 71.36% | 66.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 33.20% | 117.08% | 1,123.95% | -- | -- |
| Net Income | -111.98% | 20.66% | 54.82% | 74.00% | 64.39% |
| EBIT | -42.47% | 16.10% | 52.89% | 62.54% | 60.81% |
| EBITDA | -57.83% | 6.47% | 47.28% | 57.59% | 59.71% |
| EPS Basic | 6.65% | 50.12% | 61.89% | 75.07% | 65.12% |
| Normalized Basic EPS | 9.53% | 50.28% | 66.04% | 69.25% | 67.03% |
| EPS Diluted | 6.68% | 50.61% | 62.19% | 75.34% | 65.48% |
| Normalized Diluted EPS | 9.53% | 50.28% | 66.04% | 69.25% | 67.03% |
| Average Basic Shares Outstanding | 148.36% | 72.12% | 15.86% | 3.37% | 2.29% |
| Average Diluted Shares Outstanding | 148.36% | 72.12% | 15.86% | 3.37% | 2.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |